These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19384569)

  • 1. Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.
    Gregório ML; Wietzikoski EC; Ferro MM; Silveira JL; Vital MA; Da Cunha C
    Neurotox Res; 2009 May; 15(4):359-66. PubMed ID: 19384569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
    Vorobyov VV; Schibaev NV; Morelli M; Carta AR
    Brain Res; 2003 May; 972(1-2):177-85. PubMed ID: 12711091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
    Frau L; Morelli M; Simola N
    Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is nicotine protective against Parkinson's disease? An experimental analysis.
    García-Montes JR; Boronat-García A; López-Colomé AM; Bargas J; Guerra-Crespo M; Drucker-Colín R
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):897-906. PubMed ID: 23131151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
    Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
    Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
    Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
    Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
    Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
    Petri D; Pum M; Vesper J; Huston JP; Schnitzler A
    Behav Brain Res; 2013 Sep; 252():58-67. PubMed ID: 23727148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
    Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
    Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL; Cheetham SC; Jenner P
    Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdialysis study of striatal dopamine in MPTP-hemilesioned rats challenged with apomorphine and amphetamine.
    Dombrowski PA; Carvalho MC; Miyoshi E; Correia D; Bortolanza M; Dos Santos LM; Wietzikoski EC; Eckart MT; Schwarting RK; Brandão ML; Da Cunha C
    Behav Brain Res; 2010 Dec; 215(1):63-70. PubMed ID: 20600337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.
    Hudson JL; van Horne CG; Strömberg I; Brock S; Clayton J; Masserano J; Hoffer BJ; Gerhardt GA
    Brain Res; 1993 Oct; 626(1-2):167-74. PubMed ID: 8281427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2007 May; 192(1):49-59. PubMed ID: 17265149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
    Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
    Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission.
    Da Cunha C; Wietzikoski EC; Ferro MM; Martinez GR; Vital MA; Hipólide D; Tufik S; Canteras NS
    Behav Brain Res; 2008 Jun; 189(2):364-72. PubMed ID: 18328580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracarotid Infusion of Mesenchymal Stem Cells in an Animal Model of Parkinson's Disease, Focusing on Cell Distribution and Neuroprotective and Behavioral Effects.
    Cerri S; Greco R; Levandis G; Ghezzi C; Mangione AS; Fuzzati-Armentero MT; Bonizzi A; Avanzini MA; Maccario R; Blandini F
    Stem Cells Transl Med; 2015 Sep; 4(9):1073-85. PubMed ID: 26198165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.